### 2.2.1 In vitro / physico-chemical Data

A literature search was performed to collect available information on physiochemical properties of efavirenz. The obtained information from literature is summarized in the table below. 

| **Parameter**   | **Unit** | **Value**       | Source                                                       | **Description**                                 |
| :-------------- | -------- | --------------- | ------------------------------------------------------------ | ----------------------------------------------- |
| MW              | g/mol    | 315.675         | https://www.drugbank.ca/                                     | Molecular weight                                |
| pK<sub>a</sub>  | 10.1     | (base)          | [Rabel 1996](#5-references)                                | Acid dissociation constant                      |
| Solubility (pH) | mg/L     | 11.5 (6.4) | [Cristofoletti 2013](#5-references)        | Water solubility                               |
| logP            |          | 2.07, 4.6       | [Almond 2005](#5-references), https://www.drugbank.ca/     | Partition coefficient between octanol and water |
| logD            |          | 5.1       | [Janneh 2009](#5-references) | Partition coefficient between octanol and buffer solution |
| fu              |         | 0.006 [0.004 - 0.015] | [Almond 2005](#5-references) | Fraction unbound in plasma                      |
| Emax (CYP3A4) |          | 7.27, 3.15 (average 5.21) | [Shou 2008](#5-references) | Maximum induction effect |
| EC50 (CYP3A4) | µmol/l | 12.5, 2.18 (average 7.34) | [Shou 2008](#5-references) | Concentration at half maximum induction |
| Emax (CYP2B6) |          | 5.1       | [Ke 2016](#5-references) | Maximum induction effect |
| EC50 (CYP2B6) | µmol/l | 5.1       | [Ke 2016](#5-references) | Concentration at half maximum induction |


### 2.2.2 Clinical Data

A literature search was performed to collect available clinical data on efavirenz in healthy adults.

#### 2.2.2.1 Model Building

The following studies were used for model building:

| Publication                  | Arm / Treatment / Information used for model building        |
| :--------------------------- | :----------------------------------------------------------- |
| [Mouly 2002](#5-references)  | Healthy subjects receiving a single oral dose of 200 and 400 mg |
| [Ogburn 2013](#5-references) | Healthy subjects receiving a single oral dose of 600 mg      |
| [Xu 2013](#5-references)     | Healthy subjects with different CYP2B6 genotypes receiving a single oral dose of 600 mg |
| [Dooley 2012](#5-references) | Healthy subjects with different CYP2B6 genotypes receiving multiple doses of 600 mg |
| [Garg 2013](#5-references)   | Healthy subjects receiving multiple doses of 600 mg          |
| [Huang 2012](#5-references)  | Healthy subjects receiving multiple doses of 600 mg          |



#### 2.2.2.2 Midazolam interaction studies used to parameterize CYP3A4 interaction

The following studies were used for parameterization of CYP3A4 interaction:

| Publication                       | Arm / Treatment / Information used for model building        |
| :-------------------------------- | :----------------------------------------------------------- |
| [Mikus 2017](#5-references)       | Healthy subjects receiving a single oral dose of  400 mg Efavirenz at t=0h, 4 mg midazolam at t=12h and a single intravenous dose of 2 mg midazolam at t=18h. |
| [Katzenmaier 2010](#5-references) | Healthy subjects receiving multiple oral doses of 400 mg efavirenz QD. On day 14, subjects receive a single oral midazolam dose of 3 mg. |
